Project Grant R44AI186712
Award Date
7/8/24
Completion Date
6/30/27
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Helixbind, Inc. (C37HLWKKAH69)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Acton, MA 01719, USA
Similar Awards
This Project Grant award, valued at $1,528,846.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop an exclusive liquid repellency-based microfluidic system for transformative, next-generation phenotypic antimicrobial susceptibility testing (AST). The key objectives are to: 1) enable direct AST using original clinical isolates without time-consuming expansion...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baebies, Inc., a Durham, North Carolina-based medical diagnostics company. This funding will support the development of a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs) and reduce overtreatment, thereby helping to prevent the emergence of antibiotic-resistant STI strains....
This federal Project Grant award, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), supports the development of a rapid and automated pathogen DNA extraction device from venous whole blood samples. The $274,858 award, effective September 1, 2024 through February 28, 2025, will enable the awardee, New England Hemolytics, Inc., to test and optimize a novel pathogen extraction technology that can decrease the time to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Anvil Diagnostics Inc. in Cambridge, MA provides $298,646 to develop a rapid diagnostic test for detecting sepsis-causing pathogens in plasma samples. The proposed technology aims to comprehensively identify and quantify a wide range of pathogens from small blood volumes within 4 hours, addressing critical limitations of current sepsis diagnostics. The innovations focus on...
This Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,000,000 in funding to Partillion Bioscience Corp, a for-profit biotechnology company in Los Angeles, California. The award supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology, called "nanovials", to enable ultra high-throughput...
This $305,000 Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a point-of-care diagnostic platform by Resonantia Diagnostics, Inc. that can rapidly identify pathogens and determine their antimicrobial susceptibility within 60 minutes. The key technical objectives of this 1-year project are to: (1) demonstrate accurate antimicrobial susceptibility testing at low pathogen loads, (2)...
This $971,664 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid point-of-care diagnostic assay for the detection of Babesia microti infection and serodiagnosis of Lyme disease. The award will support two key objectives: 1) deriving high-affinity monoclonal antibodies to capture and detect Babesia microti antigens, and 2) integrating this antigen...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $297,761 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Biological Mimetics, Inc. to develop a sensitive, rapid, and affordable CRISPR-based diagnostic test for malaria parasites. The project aims to create an instrument-free, simple-to-run diagnostic that requires no advanced training and is suitable for resource-limited regions. Key objectives include optimizing the isothermal amplification...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) aims to develop novel nanopore- and click-chemistry-based approaches for the rapid, accurate detection of sepsis-causing pathogens directly from blood, without requiring a positive blood culture. The $1,569,047 award, with a project period from July 1, 2024 to May 31, 2029, will fund the engineering of nanopore biosensors and the...